Novel drug delivery system

1. NOVEL DRUG DELIVERY
SYSTEM
R E S H M A FAT H I M A K
A S S I S TA N T P R O F E S S O R
G R A C E C O L L E G E O F P H A R M A C Y,
PA L A K K A D

2. The method by which a drug is delivered can have a significant effect on its
efficacy. Some drugs have an optimum concentration range within which
maximum benefit is derived, and concentrations above or below this range
can be toxic or produce no therapeutic benefit at all . On the other hand, the
very slow progress in the efficacy of the treatment of severe diseases, has
suggested a growing need for a multidisciplinary approach to the delivery of
therapeutics to targets in tissues.

3. From this, new ideas on controlling the pharmacokinetics,
pharmacodynamics, non-specific toxicity, immunogenicity, biorecognition,
and efficacy of drugs were generated. These new strategies, often called
drug delivery systems (DDS), which are based on interdisciplinary
approaches that combine polymer science, pharmaceutics, bioconjugate
chemistry, and molecular biology.

4. To minimize drug degradation and loss, to prevent harmful side-effects and to
increase drug bioavailability and the fraction of the drug accumulated in the
required zone, various drug delivery and drug targeting systems are currently
under development. Controlled and Novel Drug Delivery which was only a dream
or at best a possibility is now a reality. During the last decade and half
pharmaceutical and other scientists have carried out extensive and intensive
investigations in this field of drug research

5. WHY DO WE NEED NDDS
The conventional dosage forms provide drug
release immediately and it causes fluctuation of
drug level in blood depending upon dosage form.
Therefore to maintain the drug concentration
within therapeutically effective range need novel
drug delivery system.

6. • “Novel Drug delivery System (NDDS) refers to the approaches, formulations,
technologies, and systems for transporting a pharmaceutical compound in the body as
needed to safely achieve its desired therapeutic effects. It may involve scientific site-
targeting within the body, or it might involve facilitating systemic pharmacokinetics; in
any case, it is typically concerned with both quantity and duration of drug presence”.

8. Among drug carriers one can name soluble polymers, microparticles
made of insoluble or biodegradable, natural and synthetic polymers,
microcapsules, cells, cell ghosts, lipoproteins, liposomes, and
micelles. The carriers can be made slowly degradable, stimuli-reactive
(e.g., pH- or temperature-sensitive), and even targeted (e.g., by
conjugating them with specific antibodies against certain
characteristic components of the area of interest). Targeting is the
ability to direct the drug-loaded system to the site of interest.

9. Two major mechanisms can be distinguished for addressing the desired sites
for drug release:
• Passive and
• Active targeting
An example of passive targeting is the preferential accumulation of
chemotherapeutic agents in solid tumors as a result of the enhanced vascular
permeability of tumor tissues compared with healthy tissue. A strategy that
could allow active targeting involves the surface functionalization of drug
carriers with ligands that are selectively recognized by receptors on the surface
of the cells of interest. Since ligand–receptor interactions can be highly
selective, this could allow a more precise targeting of the site of interest

10. TYPES OF DRUG DELIVERY
Any drug delivery system may be defined as a system comprising of:
a) Drug formulation
b) Medical device or dosage form/technology to carry the drug inside the body
c) Mechanism for the release
Conventional drug delivery involves the formulation of the drug into a suitable form,
such as a compressed tablet for oral administration or a solution for intravenous
administration. These dosage forms have been found to have serious limitations in
terms of higher dosage required, lower effectiveness, toxicity and adverse side effects.
New drug delivery systems have been developed or are being developed to overcome
the limitation of the conventional drug delivery systems to meet the need of the
healthcare profession.

11. These systems can be characterised as controlled drug release systems and targeted
drug delivery systems.
• The therapeutic benefits of these new systems include:
• Increased efficacy of the drug
• Site specific delivery
• Decreased toxicity/side effects
• Increased convenience
• Viable treatments for previously incurable diseases
• Potential for prophylactic applications
• Better patient compliance.

12. Various Drug Delivery Systems:
Carrier based Drug Delivery System:
A) Liposomes
B) Nanoparticles
C) Microspheres
D) Monoclonal antibodies
E) Niosomes
F) Resealed erythrocytes as drug carriers

13. • Targeted Drug Delivery System
• Controlled Drug Delivery System
• Modulated Drug Delivery System
• SR – Release of initial dose & further prolonged release of drug. Also called extended release,
delayed release, prolonged release. SR means slow release of a drug substance from a dosage form
to maintain therapeutic response for extended period (8-12hrs). Time depends on dosage form.
e.g., Aspirin SR Tablet,
• CR – Release of drug in controlled release for long periods. In this the rate or speed at which the
drug is released is controlled. e.g., (Nifidipine).
Sometimes SR is called as controlled release but all
controlled release are not sustained release.

14. The drug is delivered in such a way that drug is only active in the
target area of the body (cancerous tissues) in which drug is released
over a period of time in a controlled manner. e.g., Colon targeted
drugs.
Delivery of drugs to their site of action is one of the major problem
facing the pharmaceutical industries.
TARGETED DRUG DELIVERY

15. Nanosomes
Liposomes
Niosomes
Nanoparticle
Nanosphere
Microsphere
Microparticle
Microemulsion
Nanosuspension
Micelles
List of drug carriers in NDDS

16. A liposome is a spherical vesicle having at least one lipid bilayer. The liposome can be used as a
vehicle for administration of nutrients and pharmaceutical drugs. Liposomes can be prepared by
disrupting biological membranes (such as by sonication).

17. Niosomes are lamellar structures that are microscopic in size. They constitute of non-ionic
surfactant of the alkyl or dialkyl polyglycerol ether class and cholesterol with subsequent
hydration in aqueous media.

18. Nanospheres and nanocapsules are small vesicles used to transport
drugs. Nanospheres are typically solid polymers with drugs embedded in the
polymer matrix. Nanocapsules are a shell with an inner space loaded with the
drug of interest.

19. Microspheres are characteristically free flowing powders consisting of
proteins or synthetic polymers, which are biodegradable in nature and
ideally having a particle size less than 200μm. This is the important
approach in delivering therapeutic substance to the target site in
sustained and controlled release fashion.